Receptor News and Research

RSS

New signaling pathway enhances blood stem cell transplantation outcomes

Gene therapies are used to treat many different blood disorders. However, blood stem cells often fail to achieve their full potential after transplantation.

9 Oct 2026

Polymeric nanomedicine strategies improve solid tumor immunotherapy outcomes

Solid tumors are not merely collections of malignant cells but complex ecosystems comprising tumor cells, stromal cells, and the extracellular matrix (ECM).

9 Oct 2026

Gut bacteria may help explain why endometriosis pain varies

A study of 50 women with surgically confirmed endometriosis found that differences in gut bacterial composition were associated with menstrual pain, urinary symptoms, and infertility.

9 Oct 2026

Rare dendritic cells may promote immune tolerance in metastatic cancer

This study was co-led by Steven Blum, MD. Gary Reynolds, MD, PhD, Samuel Klempner, MD, and Alexandra-Chloé Villani, PhD, jointly supervised the work at the Krantz Family Center for Cancer Research within the Mass General Brigham Cancer Institute and the Mass General Brigham Center for Immunology & Inflammatory Diseases (CIID).

8 Oct 2026

Disrupted circadian rhythms may influence tumor immunity and cancer spread

Epidemiological studies link light at night (LAN), shift work, chronic jet lag (CJL), and core clock gene mutations to higher cancer risk and aggressive spread, especially in breast and colorectal cancer.

8 Oct 2026

Consuming fat before carbohydrates reduces post-meal blood glucose

In treating diabetes, post-meal elevation of glucose levels is an important therapeutic target. Existing clinical studies indicate that eating vegetables, protein, or fat before carbohydrates can moderate a post-meal rise in blood glucose, pointing to the potential of meal-sequencing as a simple and sustainable dietary strategy.

8 Oct 2026

Potassium-rich DASH diet does not cause hyperkalemia in individuals taking blood pressure drugs

Increased consumption of potassium-rich foods that are part of the Dietary Approaches to Stop Hypertension (DASH) diet did not raise blood potassium to dangerous levels in people taking medications to lower their blood pressure, according to preliminary research presented at the American Heart Association's Hypertension Scientific Sessions 2026.

8 Oct 2026

Combination therapy overcomes immunotherapy resistance in glioblastoma

Scientists at The Wistar Institute have identified a combination treatment that overcomes two of the biggest barriers to immunotherapy in glioblastoma.

8 Oct 2026

Single tRNA controls prostate cancer identity and treatment resistance

Researchers at Fred Hutch Cancer Center have identified a previously overlooked molecular regulator that helps determine whether prostate tumors remain sensitive to treatment or evolve into a more aggressive, drug-resistant form of the disease.

7 Oct 2026

Structured support may slow weight regain after stopping GLP-1 drugs

Glucagon-like peptide-1 (GLP-1) receptor agonists are effective treatments for obesity, but discontinuation is common due to cost, insurance coverage limitations, side effects, patient preference, and other factors-commonly leading to rapid weight regain.

7 Oct 2026

UCLA researcher wins the 2026 Albany Prize for revolutionary cancer therapy discoveries

Dr. Dennis Slamon, a pioneering oncologist and researcher at the UCLA Health Jonsson Comprehensive Cancer Center, has been awarded the 2026 Albany Prize for discoveries that transformed the understanding and treatment of cancer.

6 Oct 2026

Managing misfolded proteins to prevent Parkinson’s disease

The protein alpha-synuclein is abundant in healthy brains and plays an important role in enabling communication between nerve cells. However, under certain conditions, misfolded alpha-synuclein proteins can accumulate into toxic clumps inside neurons

6 Oct 2026

Younger postmenopausal women may not get enough calcium

A small Italian study examined whether women facing heightened bone-loss risks are getting enough calcium from their diets, with particular attention to breast cancer patients receiving endocrine therapy.

6 Oct 2026

Phase III trial tests MRD-guided treatment for patients with ER-positive/HER2-negative breast cancer

Alliance Foundation Trials, LLC (AFT), a national leader in conducting innovative, practice-changing cancer clinical trials, and Natera, Inc., a global leader in cell-free DNA and precision medicine, today announced the launch of AFT-70 NAVIGATE, a randomized phase III trial evaluating a novel molecular residual disease (MRD)-guided treatment strategy for patients with intermediate and high-risk ER-positive/HER2-negative early breast cancer.

5 Oct 2026

Lipid signaling pathway helps cells survive bacterial toxin damage

Epithelial cells form the body's frontline barriers, helping keep microbes, toxins, and other harmful substances out.

5 Oct 2026

New BCR analysis method tracks immune recovery after stem cell transplantation

A research team led by Associate Professor Yohei Funakoshi, Associate Professor Kimikazu Yakushijin, and Professor Hironobu Minami of the Division of Medical Oncology/Hematology at Kobe University Hospital, together with Associate Professor Goh Ohji of the Division of Infectious Disease Therapeutics and Takaji Matsutani of Anymics Inc., has developed the pGen-SHM plot.

5 Oct 2026

Existing drug could target neuroinflammation in Alzheimer's patients

Inflammatory conditions in the brain, including traumatic brain injury and degenerative diseases like Alzheimer's could be targeted with an existing drug thanks to new research that shows it can work in brain cells.

5 Oct 2026

Enlicitide offers oral treatment option for patients avoiding cholesterol injections

In 2015, a new class of cholesterol-lowering injectable drugs called PCSK9-inhibitors was approved by the Food and Drug Administration (FDA) as a result of clinical research led by UT Southwestern.

5 Oct 2026

Dr. GPCR and Eurofins Discovery join forces to advance GPCR drug discovery

Dr. GPCR, the global knowledge hub for G protein-coupled receptor (GPCR) research and education, today announced a strategic partnership with Eurofins Discovery, the drug discovery services side of the same group behind the Eurofins DiscoverX products many in the community already know.

From Eurofins Discovery 5 Oct 2026